Prof. Santos receives a prestigious European Research Council Proof of Concept Grant
The main objective of iNANOVAC4CANCER is to establish technical and commercial viability for a personalized biohybrid and biodegradable nanovaccine platform, a novel patient-focused nanomaterial-based immunotherapy platform for the treatment of melanoma, prostate, and breast cancers with potential to expand to other cancers and diseases. The commercial aim of this activity will be to establish go/no go criteria for further development of biohybrid nanovaccine platform for cancer immunotherapy and make the critical go/no go decisions regarding the potential to (1) build a spin-off or start-up company, (2) foster academic co-development with industry, (3) out-license the technology, (4) identify further market segments to expand, and/or (5) a combination thereof.
This project is in close collaboration with Prof. Vincenzo Cerullo, Associate Professor (tenure-track) at the Faculty of Pharmacy (University of Helsinki), Prof. Anu Airaksinen, Associate Professore (tenure-track) at the Faculty of Sciences (University of Helsinki), Prof. Jarno Salonen, full Professor at the University of Turku, and the campanies Valo Therapeutics, Kolster and ttopstart.
The ERC Proof of Concept funding is made available only to those who already have an ERC award to establish proof of concept of an idea that was generated in the course of their ERC-funded projects. For more details about ERC PoC in here
Prof. Santos was an ERC Starting Grant awardee in 2013-2017 with the project "Multistage-Multifunctional Porous Silicon Nanovectors for Directed Theranostics". For more details about the previous ERC StG of Prof. Santos in here